Essure birth control lawsuit: how the substantially-completed $1.6 billion Bayer settlement framework actually worked

The Essure birth control lawsuit framework substantially resolved through one of the largest medical device settlement agreements in U.S. history. In August 2020, Bayer announced a substantial $1.6 billion settlement framework substantially resolving approximately 90% of nearly 39,000 Essure lawsuits — substantial substantive resolution covering substantial Essure claimants alleging substantial complications from Bayer's substantial permanent contraceptive device. The substantial litigation was substantially consolidated in two primary forums: the California Joint Council Coordinated Proceedings (JCCP) and the U.S. District Court for the Eastern District of Pennsylvania before Judge Malachy E. Mannion. The substantial framework substantially differed from substantial formal multidistrict litigation through substantial substantive coordinated proceedings framework — substantial substantive distinction in substantial procedural approach.

The substantive theory centered on substantial allegations that Essure substantially caused substantial complications including substantial chronic pelvic pain, substantial excessive bleeding, substantial device migration, substantial perforation of fallopian tubes and substantial uterus, substantial device breakage, substantial unintended pregnancies, substantial autoimmune reactions, substantial nickel allergic reactions (Essure substantially contained nickel coils), and substantial substantive complications requiring substantial hysterectomy or substantial subsequent surgical removal. The substantial substantive product framework involved Essure, substantial permanent contraceptive device involving substantial small metal coils substantially inserted into substantial fallopian tubes substantially intending to create substantial scar tissue substantially blocking substantial tubes. The substantial substantive product was substantially marketed as substantial non-surgical permanent birth control alternative to substantial tubal ligation — substantial substantive marketing that substantial plaintiffs substantially alleged substantially failed to substantially warn about substantial complications.

The substantial substantive Bayer corporate response framework substantially evolved through substantial multi-year procedural framework. Bayer substantially stopped selling Essure in substantial United States in substantial December 2018 — substantial substantive market withdrawal that substantial Bayer substantially attributed to substantial declining sales rather than substantial safety concerns. FDA action followed in 2019 with substantial substantive restrictions on substantial Essure marketing. Bayer substantially set aside substantial $1.4 billion in substantial second quarter 2020 financial statement substantially anticipating substantial settlement framework, then substantially announced substantial $1.6 billion settlement in substantial August 2020. The substantial settlement framework substantially resolved approximately 90% of substantial pending claims with substantial confidential individual settlement amounts and substantial Bayer's substantial substantive non-admission of liability. The substantial remaining 10% framework substantially proceeded through substantial additional negotiation and substantial individual settlement framework with substantial most claims substantially resolved by substantial early 2025. Substantial residual state court cases substantially continue in substantial California, Illinois, and New Jersey state courts.

This is how the Essure birth control lawsuit framework actually worked through substantial California JCCP and substantial E.D. Pennsylvania consolidated proceedings, the substantive theories of substantial complications, the substantial substantive Bayer December 2018 U.S. market withdrawal framework, the substantial $1.6 billion August 2020 settlement framework, and the strategic considerations for affected Essure users.

What Essure was and the alleged complications

The Essure product at issue:

Essure (manufactured by Bayer):

Permanent contraceptive device
Small metal coils inserted into fallopian tubes
Created scar tissue to block tubes
Substantial substantive permanent birth control framework
Stopped sold in U.S. December 2018

Substantial design framework:

Substantial small metal coils. Substantial:

Nickel-titanium alloy coils
Substantial substantive design
Substantial individual analysis

Substantial fallopian tube placement. Substantial:

Non-surgical insertion
Substantial substantive procedure
Substantial substantive framework

Substantial scar tissue formation. Substantial:

Substantial substantive intended effect
Blocks fallopian tubes
Substantial substantive mechanism

Substantial alleged complications

Substantial substantive framework:

1. Chronic pelvic pain. Substantial:

Most common complication alleged
Substantial daily life impact
Substantial subsequent medical care
Substantial individual analysis

2. Excessive/abnormal bleeding. Substantial:

Substantial substantive complications
Substantial subsequent medical care
Substantial individual analysis

3. Device migration. Substantial:

Device moves from intended position
Substantial substantive complications
Substantial subsequent surgical intervention

4. Perforation. Substantial:

Fallopian tube perforation
Uterine perforation
Substantial substantive complications
Substantial substantial subsequent intervention

5. Device breakage. Substantial:

Coils break/fragment
Substantial substantive complications
Substantial subsequent intervention
Substantial substantive analysis

6. Unintended pregnancies. Substantial:

Device failed contraceptive function
Substantial substantive failure
Substantial individual analysis

7. Nickel allergic reactions. Substantial:

Essure contained nickel
Substantial substantive immunologic complications
Substantial individual analysis

8. Autoimmune reactions. Substantial:

Substantial substantive immunologic complications
Substantial substantive analysis
Substantial individual analysis

9. Hysterectomy requirement. Substantial:

Subsequent hysterectomy required
Substantial substantive complications
Substantial substantive intervention
Substantial substantive impact

10. Substantial substantive subsequent surgical removal. Substantial:

Subsequent removal procedures
Substantial complex surgical intervention
Substantial substantive impact
Substantial substantive analysis

11. Substantial substantive sterilization failure. Substantial:

Substantial substantive primary function failure
Substantial substantive impact
Substantial individual analysis

12. Substantial substantive psychological harm. Substantial:

Substantial substantive complications
Substantial substantive individual analysis

The procedural history

The litigation developed through several phases:

2002. Substantial substantive Essure FDA approval (substantial original Conceptus device).

2013. Bayer substantially acquired Conceptus (substantial Essure manufacturer) for substantial $1.1 billion. Substantial substantive corporate framework.

2013-2015. Substantial growing lawsuit filings begin. Substantial individual lawsuits filed.

Substantial 2015. Substantial FDA Black Box Warning added. Substantial substantive regulatory action.

2016. Substantial coordinated proceedings substantially establish:

California Joint Council Coordinated Proceedings (JCCP)
U.S. District Court for the Eastern District of Pennsylvania
Substantial substantive consolidated framework
Substantial procedural framework

2016-2020. Substantial discovery and motion practice. Substantial individual case development.

Substantial 2017-2018. Substantial bellwether case management framework. Substantial substantive trial preparation.

December 2018. Bayer substantially stops selling Essure in substantial United States:

Substantial substantive market withdrawal
Bayer substantially attributed to declining sales
Substantial substantive corporate decision

Substantial 2019. Substantial FDA action follows substantial 2018 market withdrawal:

Substantial substantive regulatory framework
Substantial substantive analysis

Q2 2020. Bayer substantially sets aside substantial $1.4 billion:

Second quarter financial statement
Substantial substantive anticipation
Substantial substantive corporate disclosure

August 20, 2020. Bayer substantially announces substantial $1.6 billion settlement framework:

Substantial substantive framework
Substantial substantive non-admission of liability
Substantial confidential individual settlement amounts

2020-2025. Substantial individual case settlements continue. Substantial substantive resolution through substantial framework. Substantial most claims substantially resolved by substantial early 2025.

Substantial 2025-2026. Substantial residual state court cases continue:

California state court
Illinois state court
New Jersey state court
Substantial substantive framework
Substantial individual case framework

The substantial $1.6 billion settlement framework

Settlement framework structure

Substantial substantive framework:

$1.6 billion total settlement. Substantial:

Substantial substantive framework
Substantial confidential individual settlements
Substantial procedural framework

Resolution scope: Substantial:

Approximately 90% of nearly 39,000 lawsuits
Substantial substantive framework
Substantial substantive resolution

Bayer substantial non-admission of liability. Substantial:

Substantial substantive corporate position
Substantial substantive framework
Substantial substantive analysis

Substantial substantive case factors

Substantial substantive framework:

Specific injury severity. Substantial:

Substantial individual factors
Substantial substantive evaluation
Substantial procedural framework

Substantial complications. Substantial:

Substantial individual analysis
Substantial substantive evaluation
Substantial substantive framework

Substantial subsequent surgeries. Substantial:

Substantial substantive analysis
Substantial individual evaluation
Substantial substantive framework

Substantial substantive functional impact. Substantial:

Substantial individual factors
Substantial substantive evaluation

Substantial procedural framework continuing

Substantial substantive framework:

Residual state court framework. Substantial:

California, Illinois, New Jersey
Substantial individual case framework
Substantial procedural framework
Substantial substantive analysis

Substantial individual analysis required for substantial new cases. Substantial:

Substantial statute of limitations analysis
Substantial substantive framework
Substantial professional involvement valuable

Substantial substantive comparison to other women's health mass torts

The substantial framework compares to substantial related litigation:

Compared to Mirena IUD litigation: Both Bayer contraceptive devices. Mirena MDL 2434 (perforation/migration, substantially closed 2018) and MDL 2767 (pseudotumor cerebri/IIH, closed December 2020 after substantial Judge Engelmayer Daubert exclusions). Essure substantially substantially resolved through substantial $1.6 billion 2020 settlement framework (substantial substantive contrast).

Compared to ParaGard IUD MDL 2974: ParaGard substantial active framework with substantial bellwether trials. Essure substantially completed framework.

Compared to Depo-Provera litigation: Depo-Provera substantial meningioma framework, substantially building. Essure substantially completed $1.6 billion framework.

Compared to hair relaxer cancer MDL 3060: Hair relaxer substantial active framework. Essure substantially completed framework.

Compared to NEC infant formula litigation: Both involve substantial vulnerable populations. NEC substantial active framework. Essure substantially completed.

Distinctive Essure features:

Substantial $1.6 billion 2020 settlement (substantial substantive resolution)
Approximately 39,000 total claims
Approximately 90% resolved in initial settlement
California Joint Council Coordinated Proceedings (substantial JCCP framework)
U.S. District Court for the Eastern District of Pennsylvania consolidation
Judge Malachy E. Mannion (E.D. Pennsylvania)
Bayer December 2018 U.S. market withdrawal (substantial substantive corporate decision)
2019 FDA action framework
2013 Bayer acquisition of Conceptus
2002 Essure FDA approval
Substantial nickel-titanium coil design
Substantial substantive multi-injury allegation framework
Substantial pelvic pain, bleeding, migration, perforation, breakage, unintended pregnancy, nickel reactions, autoimmune, hysterectomy framework
Substantial substantive non-admission of liability
Substantial residual state court framework (CA, IL, NJ)
Substantially completed framework (substantial substantive resolution)

Eligibility framework

For substantial Essure users:

Documenting Essure implantation

Critical first step. Identify Essure implantation specifically:

Medical records (implantation procedure)
Provider records identifying Essure device
Manufacturer identification (Conceptus pre-2013, Bayer post-2013)
Insertion date
Removal date (if applicable)
Substantial substantive documentation requirement

Important note. Many contraceptive devices:

Essure (this litigation — substantially completed)
Mirena IUD (substantial substantive separate frameworks)
ParaGard copper IUD (MDL 2974, active)
Various other manufacturer products

The specific product determines which litigation framework applies.

Documenting the injury

Strong case requirements:

Substantial diagnostic documentation:

Imaging studies (X-rays, CT, MRI)
Hysterosalpingogram results
Substantial documentation

Specific injury documentation:

Pelvic pain treatment records
Bleeding treatment records
Surgical revision records
Hysterectomy records (if applicable)
Pathology of removed device (if applicable)
Substantial complications

Substantial substantive medical evaluation supporting causation. Substantial:

Treating physician statements
Substantial documentation of connection
Substantial substantive framework

Statute of limitations analysis

Most states have 2-4 year limitations from injury or discovery:

Discovery rule may apply
Substantial individual variation
Specific state law analysis required
Substantial counsel evaluation needed

Substantial substantive framework for new Essure cases:

Substantial substantive procedural framework:

MDL/coordinated proceedings substantially completed
Some state courts substantially continue (CA, IL, NJ)
Substantial individual analysis required
Substantial professional involvement valuable

Strategic considerations

For affected Essure users:

Identify Essure implantation specifically. Critical first step:

Medical records
Provider identification
Manufacturer verification (Conceptus pre-2013, Bayer post-2013)
Product identification (Essure specifically)
Insertion and removal dates
Substantial documentation requirement

Address the substantial completed framework. Substantial:

$1.6 billion settlement framework substantially completed
Substantial procedural framework approaching completion
Substantial residual state court framework
Substantial individual analysis required

Engage experienced women's health mass tort counsel. Substantial:

Essure-specific experience valuable
Substantial procedural framework
Statute of limitations defenses
Substantial firm-specific Bayer experience valuable

Document the injury comprehensively. Strong cases include:

Imaging studies
Treatment records
Surgical removal records
Pathology of removed device
Treating physician opinions
Functional impact documentation

Address the statute of limitations carefully. Bayer raises substantial defenses:

2-4 year periods in most states
Discovery rule applicability
Specific state law analysis
Substantial counsel evaluation needed

Document subsequent medical treatment. Strong cases include:

All medical care related to Essure
Surgical removal documentation
Complication treatment
Ongoing pain management
Functional impact

Coordinate with treating physicians. OB/GYNs and other treating physicians are important witnesses. Their assessment of causation strengthens cases.

Plan for the substantial growth loss when accessing retirement funds. Some plaintiffs:

Need retirement funds for medical expenses
§72(t) early withdrawal substantial cost
Substantial coordination required
May benefit from medical expense exception

Address related tax planning. Personal injury settlements for physical injuries are tax-free under IRC §104(a)(2). Coordinate with tax counsel for substantial settlements. Component allocation (physical injury vs. emotional distress) affects tax treatment.

Watch the wrongful death framework. Some severe cases:

Substantial complications causing death
Substantial state law variation
Estate has standing
Surviving family members may have separate claims

Document the lifestyle impact. Strong cases show:

Pre-Essure functional baseline
Loss of function post-Essure
Inability to return to work
Recreational activity loss
Daily life impact

Plan for state court alternatives if available. Substantial:

California, Illinois, New Jersey state courts
Substantial procedural framework
Substantial state-specific law
Substantial counsel coordination

Address the multiple contraceptive device manufacturer landscape carefully. Many products:

Essure (this litigation — substantially completed)
Mirena IUD (substantial substantively completed MDLs with substantial emerging breast cancer framework)
ParaGard copper IUD (MDL 2974, active)
Various other manufacturer products

Identify specific product; substantially different procedural framework for each.

Watch substantial Bayer corporate framework. Substantial:

Substantial corporate financial capacity
Substantial substantive framework
Substantial procedural framework
Substantial multi-product Bayer litigation (Roundup, Mirena, Essure, Yaz/Yasmin)

Address the time-sensitive nature. Substantial:

Statute of limitations running
Substantial individual deadlines
Substantial counsel evaluation needed
Substantial procedural framework

Plan substantial removal documentation if applicable:

Surgical reports
Pathology of removed device
Substantial medical documentation
Substantial procedural framework

Document substantial nickel allergy framework if applicable:

Substantial substantive analysis
Substantial individual analysis
Substantial professional involvement valuable

Address substantial substantive autoimmune reaction framework if applicable:

Substantial substantive immunologic analysis
Substantial individual analysis
Substantial professional involvement valuable

Plan substantial hysterectomy framework if applicable:

Substantial substantive impact
Substantial substantive analysis
Substantial substantive framework

Watch substantial sterilization failure framework if applicable:

Substantial substantive impact
Substantial individual analysis
Substantial substantive framework

Plan substantial state court framework strategically. Substantial:

California JCCP framework substantial
Illinois state court substantial
New Jersey state court substantial
Substantial procedural framework
Substantial professional involvement valuable

Coordinate with LLC asset protection if substantial business assets at risk. Substantial settlements may affect:

Business asset planning
Estate planning
Substantial coordination required

Plan for substantial Bayer corporate framework. Substantial:

Substantial corporate financial capacity
Substantial substantive framework
Substantial procedural framework

Address substantial federal preemption considerations. Substantial:

FDA pre-market approval defense (substantial Class III device)
Substantial substantive defense by Bayer
Substantial procedural framework
Substantial professional analysis

Plan substantial individual case framework given completed primary settlement. Substantial:

Substantial individual analysis
Substantial procedural framework
Substantial professional involvement valuable

Engage qualified counsel. Substantial:

Women's health mass tort attorneys
Essure-specific experience valuable
Substantial professional benefit
Substantial procedural framework

For affected Essure users, the substantial litigation framework reflects substantial historical procedural realities through the substantially completed $1.6 billion 2020 Bayer settlement framework that substantially resolved approximately 90% of nearly 39,000 Essure lawsuits substantially consolidated in the California Joint Council Coordinated Proceedings (JCCP) and the U.S. District Court for the Eastern District of Pennsylvania before Judge Malachy E. Mannion. The substantial substantive theory — that Essure substantially caused substantial complications including substantial chronic pelvic pain, substantial excessive bleeding, substantial device migration, substantial perforation of fallopian tubes and uterus, substantial device breakage, substantial unintended pregnancies, substantial nickel allergic reactions, substantial autoimmune reactions, substantial hysterectomy requirement, and substantial subsequent surgical removal — substantially demonstrates the substantial substantive defect theory that drove substantial $1.6 billion settlement framework with substantial Bayer's substantial non-admission of liability. The substantial substantive Bayer corporate framework substantially evolved through substantial multi-year procedural framework including substantial 2013 Bayer acquisition of Conceptus (substantial Essure original manufacturer), substantial 2015 FDA Black Box Warning, substantial 2016 substantial coordinated proceedings establishment, substantial December 2018 U.S. market withdrawal (substantial substantive corporate decision Bayer substantially attributed to declining sales rather than substantial safety concerns), substantial 2019 FDA action, substantial Q2 2020 substantial $1.4 billion provision in substantial Bayer financial statement, and substantial August 2020 substantial $1.6 billion settlement announcement. With substantial most claims substantially resolved by substantial early 2025 and substantial residual state court cases substantially continuing in substantial California, Illinois, and New Jersey state courts, the substantial procedural framework substantially provides substantial limited opportunity for substantial new Essure cases given substantial statute of limitations considerations and substantial substantial primary settlement substantially completed framework. The work for substantial affected Essure users is in identifying substantial specific Essure implantation through substantial medical records (distinguishing from substantial similar contraceptive devices including Mirena IUD with substantial substantively completed MDL frameworks and substantial emerging breast cancer claims, ParaGard copper IUD with substantial active MDL 2974 framework, and substantial other manufacturer products), documenting substantial complications comprehensively through substantial imaging studies, substantial surgical removal records, substantial pathology of removed device, substantial treating physician opinions, and substantial functional impact documentation, addressing substantial federal preemption challenges through substantial professional analysis given the substantial Essure Class III FDA pre-market approval framework, engaging experienced women's health mass tort counsel familiar with both the substantial substantively completed Essure framework and the substantial residual state court frameworks in substantial California, Illinois, and New Jersey, addressing substantial statute of limitations through substantial discovery rule analysis where applicable, and substantial individual case analysis given the substantial substantively completed primary settlement framework administered through substantial coordinated proceedings framework that substantially substantially resolved substantial 39,000 claims through substantial Bayer's substantial $1.6 billion settlement framework.